DRNA - Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

• Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation.
• 60 mg AB-729 given once every four weeks had achieved a similar HBsAg decline for patients compared to those who took 60 mg AB-729 given once every eight weeks.
• There will be initiation of two phase 2 combination studies using AB-729 given once every eight weeks with other approved or investigational agents in the 2nd half of 2021.
• Preliminary results from the phase 1a/1b study using AB-836 in healthy volunteers and those with chronic Hepatitis B will be released in the second half of 2021.

For further details see: